GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE330nnn/GSE330160/primaryOK200TranscriptomicsRattus norvegicusExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE330160GEOGSEfalseApelin analog treatment reverses severe pulmonary arterial hypertension and right ventricular heart failurePulmonary arterial hypertension (PAH) is a progressive disease marked by pulmonary vascular remodeling, elevated pulmonary pressures, and right ventricular (RV) failure. In this study, a sugen-hypoxia rat model of PAH was used to evaluate a novel, degradation-resistant apelin analog targeting the apelinergic pathway, which is implicated in pulmonary vascular remodeling. Treatment with the apelin analog reversed key pathological features of PAH, including pulmonary vascular lesions, elevated pulmonary arterial pressures, RV dilation and dysfunction, and early cardiorenal syndrome. The therapy also reduced RV cardiomyocyte and fibroblast activation caused by pressure overload. Single-nucleus RNA sequencing of the lungs and RV demonstrated that apelin analog treatment activated protective molecular programs, notably restoring balance between protective BMPR2 signaling and pathogenic TGFBR2 signaling. Overall, these findings suggest that exogenous apelin therapy may represent a promising strategy to reverse pulmonary vascular and cardiac remodeling in PAH and warrants further clinical investigation.2026/05/22GSE330160GSM9720159GSM9720156GSM9720177GSM9720155GSM9720158GSM9720157GSM9720174GSM9720152GSM9720173GSM9720176GSM9720154GSM9720153GSM9720175GSM9720170GSM9720172GSM9720171GSM9720167GSM9720166GSM9720169GSM9720168GSM9720163GSM9720162GSM9720165GSM9720164GSM9720161GSM972016025947330160Rattus norvegicus